Medical management of Cushing's disease: what is the future? (Q36236884)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

review article

0 references

title

Medical management of Cushing's disease: what is the future? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

pituitary-dependent Cushing's disease

3 February 2020

main subject

6 references

24 March 2019

25 April 2019

13 November 2019

17 November 2019

20 November 2019

19 December 2019

1 reference

13 November 2019

1 reference

17 November 2019

1 reference

20 November 2019

nerve tissue proteins

1 reference

19 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Stephan Petersenn

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 September 2012

7 references

24 March 2019

25 April 2019

13 November 2019

17 November 2019

20 November 2019

19 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

7 references

24 March 2019

25 April 2019

13 November 2019

17 November 2019

20 November 2019

19 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

330-341

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11102-012-0397-5

3 February 2020

exact match

0 references

cites work

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Management of Cushing disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Drugs in the medical treatment of Cushing's syndrome

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Late recurrences of Cushing's disease after initial successful transsphenoidal surgery

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Mifepristone (RU 486) in Cushing's syndrome

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Treatment options for Cushing disease after unsuccessful transsphenoidal surgery

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Dopamine agonists and the risk of cardiac-valve regurgitation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Long term control of hypercortisolism with fluconazole: case report and in vitro studies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

PPAR-gamma in Cushing's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Medical therapy of Cushing's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Genomic structure and transcriptional regulation of the human somatostatin receptor type 2.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Medical therapy for Cushing's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Somatostatin receptor subtype gene expression in pituitary adenomas

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

The medical treatment of Cushing's syndrome

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

The use of ketoconazole as an inhibitor of steroid production

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Hepatic reactions associated with ketoconazole in the United Kingdom

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

The effect of o,p'-DDD on adrenal steroid replacement therapy requirements

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Quality of life after laparoscopic bilateral adrenalectomy for Cushing's disease

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Octreotide exerts different effects in vivo and in vitro in Cushing's disease

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Ketoconazole Blocks Testosterone Synthesis

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Ketoconazole Blocks Adrenal Steroid Synthesis

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Sustained Remission of Cushing's Disease with Mitotane and Pituitary Irradiation

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Response to neurotransmitter modulating drugs in patients with Cushing's disease

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Repeat transsphenoidal surgery for Cushing's disease

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin).

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

29 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Regulation of ghrelin secretion by somatostatin analogs in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Dopamine D2 receptor gene expression in human adenohypophysial adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Dopamine receptor expression and function in corticotroph pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Cabergoline monotherapy in the long-term treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Merits and pitfalls of mifepristone in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Ultrastructure of adrenal cortex of the dog during treatment with DDD

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Somatostatin receptor subtype gene expression in pituitary adenomas

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3443360

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

22 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0397-5

Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine

21 January 2018

1 reference

12 December 2020

Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome

1 reference

12 December 2020

Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome

1 reference

12 December 2020

Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome

1 reference

12 December 2020

Measurement of urinary free cortisol by current immunoassays: need for sex-dependent reference ranges to define hypercortisolism

1 reference

12 December 2020

Amphenone: toxicity and effects on adrenal and thyroid function in man

1 reference

12 December 2020

Cholesterol metabolism during ketoconazole treatment in man

1 reference

12 December 2020

Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation

1 reference

12 December 2020

Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease

1 reference

12 December 2020

Metyrapone in long-term management of Cushing's disease

1 reference

12 December 2020

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

12 December 2020

RU 486 inhibits peripheral effects of glucocorticoids in humans

1 reference

12 December 2020

Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism

1 reference

12 December 2020

A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease

1 reference

12 December 2020

Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D

1 reference

12 December 2020

Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas

1 reference

12 December 2020

Inhibition of corticosteroid secretion by amphenone in a patient with adrenocortical carcinoma

1 reference

12 December 2020

Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors

1 reference

12 December 2020

Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

1 reference

12 December 2020

1 reference

12 December 2020

Long-term treatment of central Cushing's syndrome with rosiglitazone

1 reference

12 December 2020

Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay

1 reference

12 December 2020

10.1007/S11102-012-0397-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674211%20AND%20SRC:MED&resulttype=core&format=json